Literature DB >> 8638629

Core decompression in avascular necrosis of the hip in sickle-cell disease.

L A Styles1, E P Vichinsky.   

Abstract

Sickle-cell disease (SCD) is the most common cause of avascular necrosis (AVN) of the hip in childhood. It results in significant physical impairment and chronic pain, and often progresses to require hip replacement. Conservative therapy is ineffective. We evaluated whether core decompression can arrest progression of AVN. We performed 13 coring procedures in 10 patients with SCD and AVN. Patients ranged from age 9-21 years at diagnosis (mean, median age, 15 years); five hips were stage I, six hips were stage II, and two hips were stage III. Mean follow-up on these patients was 3.7 years. Efficacy of the procedure was evaluated by clinical improvement in pain, radiographic progression, and need for further surgery. All 5 stage I patients had substantial improvement in pain, and only one showed X-ray progression. Five of the 6 (83%) stage II patients had improvement in pain, and 2 patients progressed on X-ray. Both stage III patients progressed on X-ray, but one was clinically improved. None of the 10 patients has required further surgery. Our results demonstrate that in early AVN, core decompression was beneficial for almost all patients, even with progression on X-ray. Core decompression should be considered in the management of SCD patients with early AVN.

Entities:  

Mesh:

Year:  1996        PMID: 8638629     DOI: 10.1002/(SICI)1096-8652(199606)52:2<103::AID-AJH6>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

Review 1.  Managing sickle cell disease.

Authors:  Susan Claster; Elliott P Vichinsky
Journal:  BMJ       Date:  2003-11-15

Review 2.  Rheumatologic manifestations of benign and malignant haematological disorders.

Authors:  Vinod Ravindran; Parameswaran Anoop
Journal:  Clin Rheumatol       Date:  2011-06-23       Impact factor: 2.980

Review 3.  Sclerotic bone lesions caused by non-infectious and non-neoplastic diseases: a review of the imaging and clinicopathologic findings.

Authors:  Vaibhav Gulati; Majid Chalian; Jaehyuck Yi; Uma Thakur; Avneesh Chhabra
Journal:  Skeletal Radiol       Date:  2020-10-11       Impact factor: 2.199

4.  Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California.

Authors:  Oyebimpe Adesina; Ann Brunson; Theresa H M Keegan; Ted Wun
Journal:  Blood Adv       Date:  2017-07-11

5.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18

6.  Surgical and obstetric outcomes in adults with sickle cell disease.

Authors:  Soheir Adam; Jude Jonassaint; Hillary Kruger; Melanie Kail; Eugene P Orringer; James R Eckman; Allison Ashley-Koch; Marilyn J Telen; Laura M De Castro
Journal:  Am J Med       Date:  2008-10       Impact factor: 4.965

7.  Total THA in adult osteonecrosis related to sickle cell disease.

Authors:  Philippe Hernigou; Sebastien Zilber; Paolo Filippini; Gilles Mathieu; Alexandre Poignard; Frederic Galacteros
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

Review 8.  Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia.

Authors:  Mariël L Te Winkel; Rob Pieters; Ernst-Jan D Wind; J H J M Gert Bessems; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

Review 9.  Surgical management of osteonecrosis of the femoral head in patients with sickle cell disease.

Authors:  Atul F Kamath; Michael H McGraw; Craig L Israelite
Journal:  World J Orthop       Date:  2015-11-18

10.  Massive septic pelvic osteolysis following revision total hip arthroplasty in a patient with sickle cell anemia: clinical presentation and review of the literature.

Authors:  Panagiotis Korovessis; Thomas Repantis
Journal:  Eur J Orthop Surg Traumatol       Date:  2011-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.